-
FRONT ONCOL 2021 10.3389/fonc.2021.596364
Deep Learning-Based Prediction Model for Breast Cancer Recurrence Using Adjuvant Breast Cancer Cohort in Tertiary Cancer Center Registry
Kim1, JY; Lee, YS; Yu, J; Park, Y; Lee, SK; Lee, M; Lee, JE; Kim, SW; Nam, SJ; Park, YH; Ahn, JS; Kang, M; Im, YH
View PubMed
-
FRONT ONCOL 2021 10.3389/fonc.2021.653243
The Role of Chemotherapy in Patients With HER2-Negative Isolated Locoregional Recurrence of Breast Cancer: A Multicenter Retrospective Cohort Study
Lee1, K; Sim, SH; Kang, EJ; Seo, JH; Chae, H; Lee, KS; Kim, JY; Ahn, JS; Im, YH; Park, S; Park, YH; Park, IH
View PubMed
-
DIAGNOSTICS 2021 10.3390/diagnostics11020370
Local Laboratory Testing of Germline BRCA Mutations vs. Myriad: A Single-Institution Experience in Korea
Hong1, J; Lee, J; Kwon, M; Kim, JY; Kim, JW; Ahn, JS; Im, YH; Park, YH
View PubMed
-
NAT COMMUN 2020 10.1038/s41467-020-19933-0
Chemotherapy induces dynamic immune responses in breast cancers that impact treatment outcome
Park1, YH; Lal, S; Lee, JE; Choi, YL; Wen, J; Ram, S; Ding, Y; Lee, SH; Powell, E; Lee, SK; Yu, JH; Ching, KA; Nam, JY; Kim, SW; Nam, SJ; Kim, JY; Cho, SY; Park, S; Kim, J; Hwang, S; Kim, YJ; Bonato, V; Fernandez, D; Deng, S; Wang, S; Shin, H; Kang, ES; Park, WY; Rejto, PA; Bienkowska, J; Kan, Z
View PubMed
-
ANN TRANSL MED 2020 10.21037/atm-20-3466
Treatment strategy for papillary renal cell carcinoma type 2 a case series of seven patients treated based on next generation sequencing data
Kim1, JY; Jeong, HO; Heo, DS; Keam, B; Moon, KC; Kwak, C; Jang, J; Kim, S; Kim, JI; Lee, S; Lee, SH
View PubMed
-
SCI REP-UK 2020 10.1038/s41598-020-75620-6
The incidence and clinical features of PEGylated filgrastim-induced acute aortitis in patients with breast cancer
Lee1, SY; Kim, EK; Kim, JY; Park, TK; Choi, SH; Im, YH; Kim, MY; Park, YH; Kim, DK
View PubMed
-
J IMMUNOTHER CANCER 2020 10.1136/jitc-2020-001199
Clinical advantage of targeted sequencing for unbiased tumor mutational burden estimation in samples with low tumor purity
Hong1, TH; Cha, H; Shim, JH; Lee, B; Chung, J; Lee, C; Kim, NKD; Choi, YL; Hwang, S; Lee, Y; Park, S; Jung, HA; Kim, JY; Park, YH; Sun, JM; Ahn, JS; Ahn, MJ; Park, K; Lee, SH; Park, WY
View PubMed
-
MOL CANCER RES 2020 10.1158/1541-7786.MCR-19-1108
Clinical Characteristics and Exploratory Genomic Analyses of Germline BRCA1 or BRCA2 Mutations in Breast Cancer
Park1, S; Lee, E; Park, S; Lee, S; Nam, SJ; Kim, SW; Lee, JE; Yu, JH; Kim, JY; Ahn, JS; Im, YH; Park, WY; Park, K; Park, YH
View PubMed
-
BREAST CANCER RES TR 2020 10.1007/s10549-020-05874-1
Prognostication of a 13-immune-related-gene signature in patients with early triple-negative breast cancer
Kim1, JY; Jung, HH; Sohn, I; Woo, SY; Cho, H; Cho, EY; Lee, JE; Kim, SW; Nam, SJ; Park, YH; Ahn, JS; Im, YH
View PubMed
-
BREAST CANCER RES TR 2020 10.1007/s10549-020-05891-0
Clinical implications of HER2 mRNA expression and intrinsic subtype in refractory HER2-positive metastatic breast cancer treated with pan-HER inhibitor, poziotinib
Kim1, JY; Park, K; Im, SA; Jung, KH; Sohn, J; Lee, KS; Kim, JH; Yang, Y; Park, YH
View PubMed
-
SCI REP-UK 2020 10.1038/s41598-020-70584-z
Cytokine profiling in serum-derived exosomes isolated by different methods
Jung1, HH; Kim, JY; Lim, JE; Im, YH
View PubMed
-
CANCERS 2020 10.3390/cancers12051306
Clinical Characteristics of Korean Breast Cancer Patients Who Carry Pathogenic Germline Mutations in Both BRCA1 and BRCA2: A Single-Center Experience
Hur1, JY; Kim, JY; Ahn, JS; Im, YH; Lee, J; Kwon, M; Park, YH
View PubMed
-
LANCET ONCOL 2019 10.1016/S1470-2045(19)30565-0
Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial
Park1, YH; Kim, TY; Kim, GM; Kang, SY; Park, IH; Kim, JH; Lee, KE; Ahn, HK; Lee, MH; Kim, HJ; Kim, HJ; Lee, JI; Koh, SJ; Kim, JY; Lee, KH; Sohn, J; Kim, SB; Ahn, JS; Im, YH; Jung, KH; Im, SA
View PubMed
-
BREAST CANCER RES TR 2019 10.1007/s10549-019-05400-y
Exploratory biomarker analysis from a phase II clinical trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine for HER2-negative metastatic breast cancer patients (KCSG BR13-11)
Kim1, JY; Lee, E; Park, K; Im, SA; Sohn, J; Lee, KS; Chae, YS; Kim, JH; Kim, TY; Jung, KH; Park, YH
View PubMed
-
INT J CANCER 2019 10.1002/ijc.32188
Molecular alterations and poziotinib efficacy, a pan-HER inhibitor, in human epidermal growth factor receptor 2 (HER2)-positive breast cancers: Combined exploratory biomarker analysis from a phase II clinical trial of poziotinib for refractory HER2-positive breast cancer patients
Kim1, JY; Lee, E; Park, K; Jung, HH; Park, WY; Lee, KH; Sohn, J; Lee, KS; Jung, KH; Kim, JH; Lee, KH; Im, SA; Park, YH
View PubMed
-
KOREAN JOURNAL OF INTERNAL MEDICINE 2019 10.3904/kjim.2017.226
Clinical activity of fulvestrant in metastatic breast cancer previously treated with endocrine therapy and/or chemotherapy
Heo1, MH; Kim, HK; Lee, H; Kim, JY; Ahn, JS; Im, YH; Park, YH
View PubMed
-
CANCER COMMUN 2019 10.1186/s40880-019-0375-7
Quality of life outcomes including neuropathy-associated scale from a phase II, multicenter, randomized trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy for HER2-negative metastatic breast cancer: Korean Cancer Study Group Trial (KCSG BR13-11)
Kim1, JY; Park, S; Im, SA; Kim, SB; Sohn, J; Lee, KS; Chae, YS; Lee, KH; Kim, JH; Im, YH; Kim, TY; Lee, KH; Ahn, JH; Kim, GM; Park, IH; Lee, SJ; Han, HS; Kim, SH; Jung, KH; Park, YH
View PubMed
-
CANCER RES TREAT 2019 10.4143/crt.2018.262
Early Decline in Left Ventricular Ejection Fraction Can Predict Trastuzumab-Related Cardiotoxicity in Patients with Breast Cancer: A Study Using 13 Years of Registry Data
Kim1, EK; Cho, J; Kim, JY; Chang, SA; Park, SJ; Choi, JO; Lee, SC; Ahn, JS; Park, SW; Im, YH; Jeon, ES; Park, YF
View PubMed
-
CANCER RES TREAT 2019 10.4143/crt.2018.342
Discordance of the PAM50 Intrinsic Subtypes Compared with Immunohistochemistry-Based Surrogate in Breast Cancer Patients: Potential Implication of Genomic Alterations of Discordance
Kim1, HK; Park, KH; Kim, Y; Park, SE; Lee, HS; Lim, SW; Cho, JH; Kim, JY; Lee, JE; Ahn, JS; Im, YH; Yu, JH; Park, YH
View PubMed
-
ONCOL LETT 2019 10.3892/ol.2018.9754
Clinical features and prognosis of breast cancer with gastric metastasis
Hong1, J; Kim, Y; Cho, J; Lim, SW; Park, SE; Kim, HK; Lee, H; Cho, SY; Kim, JY; Ahn, JS; Im, YH; Park, YH
View PubMed
-
BMC CANCER 2019 10.1186/s12885-018-5258-9
Does guideline non-adherence result in worse clinical outcomes for hormone receptor-positive and HER2-negative metastatic breast cancer in premenopausal women?: result of an institution database from South Korea
Kim1, HK; Lee, SH; Kim, YJ; Park, SE; Lee, HS; Lim, SW; Cho, JH; Kim, JY; Ahn, JS; Im, YH; Yu, JH; Park, YH
View PubMed
-
EUR J CANCER 2018 10.1016/j.ejca.2018.08.004
Fulvestrant plus goserelin versus anastrozole plus goserelin versus goserelin alone for hormone receptor-positive, HER2-negative tamoxifen-pretreated premenopausal women with recurrent or metastatic breast cancer (KCSG BR10-04): a multicentre, open-label, three-arm, randomised phase II trial (FLAG study)
Kim1, JY; Im, SA; Jung, KH; Ro, J; Sohn, J; Kim, JH; Park, YH; Kim, TY; Kim, SB; Lee, KS; Kim, GM; Kim, SH; Kim, S; Ahn, JS; Lee, KH; Ahn, JH; Park, IH; Im, YH
View PubMed
-
BREAST CANCER RES TR 2018 10.1007/s10549-018-4858-z
Validation of the new AJCC eighth edition of the TNM classification for breast cancer with a single-center breast cancer cohort
Kim1, JY; Lim, JE; Jung, HH; Cho, SY; Cho, EY; Lee, SK; Yu, JH; Lee, JE; Kim, SW; Nam, SJ; Park, YH; Ahn, JS; Im, YH
View PubMed
-
CLIN BREAST CANCER 2018 10.1016/j.clbc.2018.04.010
Effect of Body Mass Index on Survival in Breast Cancer Patients According to Subtype, Metabolic Syndrome, and Treatment
Cho1, WK; Choi, DH; Park, W; Cha, H; Nam, SJ; Kim, SW; Lee, JE; Yu, J; Im, YH; Ahn, JS; Park, YH; Kim, JY; Ahn, S
View PubMed
-
Oncoimmunology 2018 10.1080/2162402X.2018.1466768
Clinical implication of tumor mutational burden in patients with HER2-positive refractory metastatic breast cancer
Park1, SE; Park, K; Lee, E; Kim, JY; Ahn, JS; Im, YH; Lee, C; Jung, H; Cho, SY; Park, WY; Cristescu, R; Park, YH
View PubMed
-
NAT COMMUN 2018 10.1038/s41467-018-04129-4
Multi-omics profiling of younger Asian breast cancers reveals distinctive molecular signatures
Kan1, ZY; Ding, Y; Kim, J; Jung, HH; Chung, W; Lal, S; Cho, S; Fernandez-Banet, J; Lee, SK; Kim, SW; Lee, JE; Choi, YL; Deng, S; Kim, JY; Ahn, JS; Sha, Y; Mu, XJ; Nam, JY; Im, YH; Lee, S; Park, WY; Nam, SJ; Park, YH
View PubMed
-
J BREAST CANC 2018 10.4048/jbc.2018.21.1.91
Breast Cancer Epidemiology of the Working-Age Female Population Reveals Significant Implications for the South Korean Economy
Park1, JH; Lee, SK; Lee, JE; Kim, SW; Nam, SJ; Kim, JY; Ahn, JS; Park, W; Yu, J; Park, YH
View PubMed
-
TRANSL ONCOL 2018 10.1016/j.tranon.2017.10.002
Genetic and Clinical Characteristics of Phyllodes Tumors of the Breast
Kim1, JY; Yu, JH; Nam, SJ; Kim, SW; Lee, SK; Park, WY; Noh, DY; Nam, DH; Park, YH; Han, W; Lee, JE
View PubMed
-
EUR J CANCER 2017 10.1016/j.ejca.2017.10.002
Phase II, multicentre, randomised trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy in patients with HER2-negative metastatic breast cancer
Park1, YH; Im, SA; Kim, SB; Sohn, JH; Lee, KS; Chae, YS; Lee, KH; Kim, JH; Im, YH; Kim, JY; Kim, TY; Lee, KH; Ahn, JH; Kim, GM; Park, IH; Lee, SJ; Han, HS; Kim, SH; Jung, KH
View PubMed
-
BREAST 2017 10.1016/j.breast.2017.07.006
Isolated pachymeningeal metastasis from breast cancer: Clinical features and prognostic factors
Heo1, MH; Cho, YJ; Kim, HK; Kim, JY; Park, YH
View PubMed
-
ONCOTARGET 2017 10.18632/oncotarget.21198
Circulating tumor DNA shows variable clonal response of breast cancer during neoadjuvant chemotherapy
Kim1, JY; Park, D; Son, DS; Nam, SJ; Kim, SW; Jung, HH; Kim, YJ; Park, G; Park, WY; Lee, JE; Park, YH
View PubMed
-
BREAST CANCER RES TR 2017 10.1007/s10549-017-4268-7
A prospective randomized controlled trial of hydrating nail solution for prevention or treatment of onycholysis in breast cancer patients who received neoadjuvant/adjuvant docetaxel chemotherapy
Kim1, JY; Ok, ON; Seo, JJ; Lee, SH; Ahn, JS; Im, YH; Park, YH
View PubMed
-
Oncotarget. 2017 Apr 25;8(17):27997-28007. doi: 10.18632/oncotarget.15881.
Clinical implications of genomic profiles in metastatic breast cancer with a focus on TP53 and PIK3CA, the most frequently mutated genes
Kim JY11, Lee E2, Park K2, Park WY2, Jung HH3, Ahn JS1, Im YH1,4, Park YH1,4,3.
View PubMed
-
Oncotarget. 2017 Jan 31;8(5):8693-8706. doi: 10.18632/oncotarget.14414.
The effect of androgen receptor expression on clinical characterization of metastatic breast cancer
Kim JY11, Park K2, Lee E2, Jung HH3, Ahn JS1, Im YH1,4, Park WY2,5, Park YH1,4,3.
View PubMed
-
Cancer Res Treat. 2016 Oct;48(4):1338-1350. Epub 2016 Feb 18.
Association between Mutation and Expression of TP53 as a Potential Prognostic Marker of Triple-Negative Breast Cancer
Kim JY11, Park K2, Jung HH3, Lee E2, Cho EY4, Lee KH5, Bae SY6, Lee SK6, Kim SW6, Lee JE6, Nam SJ6, Ahn JS1, Im YH1,3, Park YH1,3.
View PubMed
-
Cancer Res Treat. 2016 Oct;48(4):1382-1388. Epub 2016 Mar 11.
Clinicopathologic Features and Long-Term Outcomes of Elderly Breast Cancer Patients: Experiences at a Single Institution in Korea
Kim HK11, Ham JS1, Byeon S1, Yoo KH1, Jung KS1, Song HN1, Cho J1, Lee JY1, Lim SH1, Kim HS1, Kim JY1, Lee JE2, Kim SW2, Nam SJ2, Lee SK2, Bae SY2, Ahn JS1, Im YH1, Park YH1.
View PubMed
-
Sci Rep. 2016 Sep 8;6:33035. doi: 10.1038/srep33035.
Statins affect ETS1-overexpressing triple-negative breast cancer cells by restoring DUSP4 deficiency
Jung HH11, Lee SH2, Kim JY2, Ahn JS2, Park YH1,2,3, Im YH2,3.
View PubMed
-
SCIENTIFIC REPORTS, AUG 22 2016, 6, DOI: 10.1038/srep31804
The relationship between nuclear factor (NF)-kappa B family gene expression and prognosis in triple-negative breast cancer (TNBC) patients receiving adjuvant doxorubicin treatment
Kim JY1, Jung HH, Ahn S, Bae S, Lee SK, Kim SW, Lee JE, Nam SJ, Ahn JS, Im YH
View PubMed
-
Sci Rep. 2016 Jun 24;6:28623. doi: 10.1038/srep28623.
Gene Expression Profiling of Breast Cancer Brain Metastasis
Lee JY11, Park K2, Lee E2, Ahn T2, Jung HH3, Lim SH1, Hong M4, Do IG4, Cho EY4, Kim DH5, Kim JY1, Ahn JS1, Im YH1,2, Park YH1,3.
View PubMed
-
BMC Cancer. 2016 Feb 22;16:138. doi: 10.1186/s12885-016-2195-3.
Prognostic value of ERBB4 expression in patients with triple negative breast cancer
Kim JY11, Jung HH2, Do IG3, Bae S4, Lee SK5, Kim SW6, Lee JE7, Nam SJ8, Ahn JS9, Park YH10,11, Im YH12,13.
View PubMed
-
Oncotarget. 2015 Dec 22;6(41):43731-42. doi: 10.18632/oncotarget.6192.
Mutational profiling of brain metastasis from breast cancer: matched pair analysis of targeted sequencing between brain metastasis and primary breast cancer
Lee JY11, Park K2, Lim SH1, Kim HS1, Yoo KH1, Jung KS1, Song HN1, Hong M3, Do IG3, Ahn T2, Lee SK4, Bae SY4, Kim SW4, Lee JE4, Nam SJ4, Kim DH5, Jung HH6, Kim JY1, Ahn JS1, Im YH1, Park YH1.
View PubMed
-
Oncotarget. 2015 Oct 13;6(31):32027-38. doi: 10.18632/oncotarget.5184.
Role of HER2 mutations in refractory metastatic breast cancers: targeted sequencing results in patients with refractory breast cancer
Park YH11,2, Shin HT3, Jung HH2, Choi YL3, Ahn T3, Park K3, Lee A4, Do IG5, Kim JY1,2, Ahn JS1, Park WY3, Im YH1,2.
View PubMed
